Comparison of pingyangmycin fibrin glue composite and pingyangmycin dexamethasone composite in the treatment of pharyngolaryngeal venous malformation.
10.3760/cma.j.cn115330-20221026-00631
- Author:
Bo WANG
1
;
Yu LIN
2
;
Hui Jun YUE
1
;
Wen Bin GUO
1
;
Lin CHEN
1
;
Ke Xing LYU
1
;
Dai Ying HUANG
3
;
Wen Bin LEI
1
Author Information
1. Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou Key Laboratory of Otorhinolaryngology, Guangzhou 510080, China.
2. Department of Otorhinolaryngology-Head and Neck Surgery, the Second Affiliated Hospital of the Medical College of Shantou University,Shantou 515041, China.
3. Department of Oral and Maxillofacial Surgery, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China.
- Publication Type:Journal Article
- MeSH:
Male;
Female;
Humans;
Fibrin Tissue Adhesive/therapeutic use*;
Retrospective Studies;
Bleomycin/adverse effects*;
Vascular Malformations/therapy*;
Dexamethasone/therapeutic use*;
Treatment Outcome
- From:
Chinese Journal of Otorhinolaryngology Head and Neck Surgery
2023;58(6):552-557
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze and compare the efficacy and safety of pingyangmycin fibrin glue composite (PFG) and pingyangmycin dexamethasone composite (PD) in the treatment of pharyngolaryngeal venous malformation (VM). Methods: The clinical data of 98 patients with pharyngolaryngeal VM who underwent sclerotherapy with pingyangmycin composite in the First Affiliated Hospital of Sun Yat-sen University from June 2013 to November 2022 were retrospectively analyzed. According to their treatment, patients were divided into PFG group (n=34) and PD group (n=64), among those patients there were 54 males and 44 females, aged 1-77(37.06±18.86)years. The lesion size, total treatment times and adverse events were recorded before and after treatment. And the efficacy was divided into three grades: recovery, effective and invalid. According to the length of VM, all patients were divided into three subgroups, to compare the differences in efficacy and treatment times between each two groups.And finally the adverse events and their treatments were analyzed. SPSS 25.0 software was used for statistical analysis. Results: The efficacy of PFG group was 94.11%(32/34), the recovery rate was 85.29%(29/34).And the efficacy of PD group was 93.75%(60/64), the recovery rate was 64.06%(41/64). No serious adverse eventst occurred in subgroup comparison, there was no statistical difference between the two groups in efficacy and the times of treatments when the length was≤3 cm (Zefficacy=1.04, ttreatment times=2.18, P>0.05); when the length was 3-5 cm, there was no significant efficacy difference between the two groups(Zefficacy=1.17, P>0.05), but the treatment times of PFG were less (ttreatment times=4.87, P<0.01); when the length≥5 cm, efficacy of PFG was significantly better than PD (Zefficacy=2.94, P<0.01), and had fewer treatments times (ttreatment times=2.16, P<0.01). There were no serious adverse events in either group during treatment and follow-up. Conclusion: Both PFG and PD are safe and effective composite sclerotherapy agent for the treatment of laryngeal VM, but PFG has a higher cure rate and fewer treatment times for massive lesions.
